Related Experiment Videos
Platelet aggregation and antithrombin III levels in diabetic children
Insights
Diabetic children showed normal platelet function but elevated antithrombin III levels. This suggests early defense mechanisms against blood clotting activation in pediatric diabetes.
Area of Science:
- Pediatric Endocrinology
- Hematology
- Vascular Biology
Background:
- Insulin-dependent diabetes mellitus (IDDM) in children can lead to microvascular complications.
- Platelet function and coagulation factors are often altered in diabetes.
- Early detection of vascular risk in pediatric diabetes is crucial.
Purpose of the Study:
- To investigate platelet function and antithrombin III levels in children with IDDM.
- To determine if subclinical microvascular changes are present in these patients.
- To explore potential early markers of altered hemostasis in pediatric diabetes.
Main Methods:
- Compared 30 children with IDDM (no clinical vascular complications) to 25 healthy controls.
- Assessed template bleeding time and ADP/adrenaline-induced platelet aggregation.
- Measured plasma antithrombin III levels and antiheparin activity (platelet factor 4).
Main Results:
- No significant differences were found in bleeding time or platelet aggregation thresholds between groups.
- Plasma antithrombin III levels were significantly higher in the diabetic children.
- Platelet factor 4 levels did not differ between diabetic children and controls.
Conclusions:
- Children with IDDM, even without clinical vascular complications, do not exhibit laboratory evidence of increased platelet activity.
- Elevated antithrombin III levels in diabetic children may indicate an early compensatory response against hypercoagulability.
- Further research is needed to understand the long-term implications of these findings in pediatric diabetes management.
Abstract:
We studied platelet function and antithrombrin III levels in 30 insulin-dependent diabetic children with no clinically evident vascular complications. 9 were in-patients and 21 were out-patients. The disease had been discovered within the previous 10 years. 25 control subjects of comparable age and body weight were studied simultaneously. Template bleeding time, threshold concentrations of ADP or adrenaline required to induce irreversible platelet aggregation and plasma antiherparin activity (platelet factor 4) did not differ significantly in control and patient groups. In contrast, the immunological levels of plasma antithrombine III were significantly higher in the diabetic group. These results suggest that diabetic children, with no clinical signs of microanigopathy, show no laboratory changes suggesting increased platelet function. The unxpected increase in the antithrombin III level could reflect a very early defense mechanism against activation of the blood clotting system.